

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic granulomatous disease for use in reducing the frequency and severity of serious infections associated with chronic granulomatous disease, or B.) Severe, malignant osteopetrosis (SMO)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant administration with nitrates or nitric oxide donors (such as amyl nitrate) in any form, B.) Concomitant administration with phosphodiesterase inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or non-specific PDE inhibitors (such as dipyridamole or theophylline), C.) Pregnancy, D.) Patients with pulmonary hypertension associated with idiopathic interstitial pneumonia
Required Medical Information	Diagnosis of one of the following A.) Pulmonary arterial hypertension (WHO group I) and diagnosis was confirmed by right heart catheterization, or B.) Chronic thromboembolic pulmonary hypertension (CTEPH, WHO group 4) and patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable (Female patients must be enrolled in the ADEMPAS REMS program)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic anaplastic lymphoma kinase positive non-small cell lung cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ALPHA1-PROTEINASE INHIBITOR

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of IgA deficiency
Required Medical Information	Diagnosis of alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency in adult patients with emphysema
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ALUNBRIG

Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of metastatic, ALK positive non-small cell lung cancer, B.) Patient has progressed on or is intolerant to Xalkori (crizotinib)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

AMBRISENTAN

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy, B.) Idiopathic pulmonary fibrosis (IPF), including those with pulmonary hypertension
Required Medical Information	Must meet both of the following A.) Diagnosis of pulmonary arterial hypertension (WHO Group I), B.) Diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ANALGESICS

Products Affected

- ASCOMP-CODEINE
- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS)
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of pulmonary Mycobacterium avium complex (MAC) infection and used as part of a combination antibacterial regimen in treatment refractory patients
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist or pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

AUBAGIO

Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Severe hepatic impairment, B.) Current treatment with leflunomide, C.) Patients who are pregnant or women of childbearing potential not using reliable contraception
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

AURYXIA

Products Affected

- AURYXIA

PA Criteria	Criteria Details
Exclusion Criteria	Iron overload syndrome (e.g. hemochromatosis)
Required Medical Information	Diagnosis of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or nephrologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

AUSTEDO

Products Affected

- AUSTEDO

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Suicidal ideation and/or untreated or inadequately treated depression, B.) Hepatic impairment, C.) Taking MAOIs, reserpine, or tetrabenazine
Required Medical Information	Diagnosis of one of the following A.) Chorea associated with Huntington's disease (Huntington's chorea), or B.) Tardive dyskinesia
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a psychiatrist or neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

BALVERSA

Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and patient has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

BOSENTAN

Products Affected

- *bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Receiving concomitant cyclosporine A or glyburide therapy, B.) Aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin at least 2 times the upper limit of normal, C.) Pregnancy
Required Medical Information	Must meet both of the following A.) Diagnosis of pulmonary arterial hypertension (WHO Group I), B.) Diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

BOSULIF

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Philadelphia chromosome-positive (Ph+) CML with resistance, relapse, or inadequate response to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tasigna [nilotinib], Sprycel [dasatinib] , or B.) Newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph + CML)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

BRAFTOVI

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of unresectable or metastatic melanoma with documented BRAF V600E or V600K mutation as detected by an FDA-approved test, B.) Used in combination with binimetinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

BRUKINSA

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of A.) Mantle Cell Lymphoma (MCL) and patient has tried one prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CABLIVI

Products Affected

- CABLIVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) and used in combination with plasma exchange and immunosuppression therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	3 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	Patients who have or are at risk for severe hemorrhage and/or patients with a recent history of bleeding or hemoptysis
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, or B.) Advanced hepatocellular carcinoma AND patient has been previously treated with sorafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CALQUENCE

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) MANTLE CELL LYMPHOMA (MCL) and patient has tried one other therapy, B.) Chronic lymphocytic leukemia, or C.) Small lymphocytic lymphoma
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	none
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of cystic fibrosis which has been confirmed by appropriate diagnostic or genetic testing, B.) Confirmation of P. aeruginosa in cultures of the airways
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CNS STIMULANTS

Products Affected

- *armodafinil*
- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Obstructive sleep apnea (OSA) confirmed by sleep lab evaluation, B.) Narcolepsy confirmed by sleep lab evaluation, or C.) Shift work disorder (SWD)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory (with history of 2 prior therapies) of one of the following A.) Chronic lymphocytic leukemia, B.) Small lymphocytic lymphoma, or C.) Follicular lymphoma
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Ankylosing spondylitis and patient has failed or is intolerant to Humira and Enbrel, B.) Moderate to severe plaque psoriasis and patient has failed or is intolerant to Humira and Enbrel, or C.) Active psoriatic arthritis and patient has failed or is intolerant to Humira and Enbrel. Screening for latent tuberculosis infection is required prior to initiation of treatment.
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist or rheumatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutation, B.) Documentation of combination therapy with vemurafenib (Zelboraf)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	Demonstrated cysteamine hypersensitivity or penicillamine hypersensitivity
Required Medical Information	Must meet both of the following A.) Diagnosis of cystinosis, B.) Patient has corneal cystine crystal accumulation
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

DALFAMPRIDINE

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of seizure. B.) Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute)
Required Medical Information	Diagnosis of multiple sclerosis and patient must demonstrate sustained walking impairment, but with the ability to walk 25 feet (with or without assistance) prior to starting dalfampridine
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

DAURISMO

Products Affected

- DAURISMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of newly diagnosed acute myeloid leukemia (AML) and used in combination with cytarabine in patients 75 years of age or older OR in patients that have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

DEFERASIROX

Products Affected

- *deferasirox oral tablet 360 mg, 90 mg*
- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Creatinine clearance less than 40 mL/min, B.) Poor performance status, C.) Platelet count less than 50 x 10 ⁹ /L, D.) Advanced malignancy, E.) High-risk myelodysplastic syndrome (MDS)
Required Medical Information	Diagnosis of one of the following A.) Chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes who have liver iron concentrations of at least 5 mg Fe/g dry weight AND serum ferritin level greater than 300 mcg/L, or B.) Chronic iron overload due to blood transfusions (transfusion hemosiderosis) as evidenced by transfusion of at least 100 mL/kg packed red blood cells AND serum ferritin level greater than 1000 mcg/L
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

DICLOFENAC TOPICAL

Products Affected

- *diclofenac sodium transdermal gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of actinic keratosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

DRONABINOL

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Anorexia associated to AIDS, or B.) Chemotherapy-induced nausea and vomiting
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, or E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy. Screening for latent tuberculosis infection is required prior to initiation of treatment.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ENDARI

Products Affected

- ENDARI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acute complications associated with sickle cell disease
Age Restrictions	5 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Lennox-Gastaut syndrome, or B.) Severe myoclonic epilepsy in infancy (Dravet syndrome)
Age Restrictions	2 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ERLEADA

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Nonmetastatic, castration-resistant prostate cancer, or B.) Metastatic, castration-sensitive prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ESBRIET

Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 801 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of idiopathic pulmonary fibrosis
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ESRD THERAPY

Products Affected

- RETACRIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Pretreatment hemoglobin levels of less than 10g/dL. Dose reduction or interruption if hemoglobin exceeds 10 g/dL (CKD not on dialysis-adult, cancer), 11 g/dL (CKD on dialysis), 12 g/dL (pediatric CKD) in addition to supporting statement of diagnosis from physician.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	3 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

FARYDAK

Products Affected

- FARYDAK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following A.) Diagnosis of multiple myeloma, B.) Medication is being used in combination with Velcade (bortezomib) and dexamethasone, C.) Patient has received at least two prior treatment regimens, including Velcade (bortezomib) and an immunomodulatory agent [eg, Revlimid (lenalidomide), Thalomid (thalidomide)]
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of severe asthma with an eosinophilic phenotype
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

FENTANYL ORAL

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Use in opioid non-tolerant patients
Required Medical Information	Must meet all of the following A.) Diagnosis of cancer-related breakthrough pain, B.) Patient is currently receiving/tolerant to around-the-clock opioid therapy for persistent cancer pain, C.) Patient and prescriber are enrolled in the TIRF REMS Access Program
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

FIRDAPSE

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	History of seizures
Required Medical Information	Diagnosis of Lambert-Eaton syndrome
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GALAFOLD

Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Fabry disease with an amenable galactosidase alpha gene (GLA) mutation
Age Restrictions	16 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GILENYA

Products Affected

- GILENYA ORAL CAPSULE 0.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure, B.) History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker, C.) Baseline QTC interval greater than or equal to 500 milliseconds, D.) Receiving concurrent treatment with Class Ia or Class III anti-arrhythmic drugs (quinidine, procainamide, amiodarone, sotalol)
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test, or B.) Metastatic squamous NSCLC, progressing after platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GLATIRAMER

Products Affected

- *glatiramer acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GOCOVRI

Products Affected

- GOCOVRI

PA Criteria	Criteria Details
Exclusion Criteria	Patients with end-stage renal disease (ESRD, CrCl below 15 ml/min/m ²)
Required Medical Information	Diagnosis of one of the following A.) Parkinsons disease and patient is experiencing dyskinesia, receiving levodopa based therapy, and has documented trial with inadequate response to amantadine immediate release, or B.) Extrapyrimalid disease and has trial with inadequate response to amantadine immediate release
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

GROWTH HORMONE

Products Affected

- OMNITROPE

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Growth promotion in pediatric patients with closed epiphyses, B.) Acute critical illness caused by complications following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure, C.) Active malignancy, D.) Active proliferative or severe nonproliferative diabetic retinopathy
Required Medical Information	Diagnosis of pediatric indication: A.) GHD and bone age at least 1 year or 2 standard deviations (SD) delayed compared with chronological age and 2 stim tests with peak GH secretion below 10 ng/mL or IGF-1/IGFBP3 level more than 2 SDS below mean if CNS pathology, h/o irradiation, or proven genetic cause, B.) SGA and birth weight or length 2 or more SDS below mean for gestational age and fails to manifest catch up growth by age 2 (height 2 or more SDS below mean for age and gender), C.) CRI and nutritional status has been optimized, metabolic abnormalities have been corrected, and patient has not had renal transplant, D.) SHOX deficiency or Noonan syndrome, E.) PWS confirmed by genetic testing, F.) Turner Syndrome confirmed by chromosome analysis. Diagnosis of GHD, CRI, SHOX deficiency, Noonan syndrome, and PWS one of the following: 1.) height more than 3 SDS below mean for age and gender, 2.) height more than 2 SDS below mean with GV more than 1 SD below mean, or 3.) GV over 1 year 2 SDS below mean. Diagnosis of adult indication: A.) childhood or adult-onset GHD confirmed by 2 standard GH stim tests: 1 test must be insulin tolerance test (ITT) with blood glucose nadir less than 40 mg/dL. If contraindicated, use a standardized stim test (i.e. arginine plus GH releasing hormone, glucagon, arginine), B.) GHD with at least 1 other pituitary hormone deficiency and failed at least 1 GH stim test, C.) GHD with panhypopituitarism (3 or more pituitary hormone deficiencies), D.) GHD with irreversible hypothalamic-pituitary structural lesions due to tumors, surgery or radiation of pituitary or hypothalamus region AND a subnormal IGF-1 (after at least 1 month off GH therapy) AND Objective evidence of GHD complications, such as: low bone density, increased visceral fat mass, or cardiovascular complications AND Completed linear growth (GV less than 2 cm/year) AND GH has been discontinued for at least 1 month (if previously receiving GH)
Age Restrictions	None

Formulary ID 20202, Ver 9

Last Updated 2/25/2020

Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PA Criteria	Criteria Details
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

HEPATITIS C

Products Affected

- *sofosbuvir-velpatasvir*
- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must submit documentation of HCV genotype, subtype and quantitative HCV RNA (viral load) testing any time prior to therapy. Must document the following within 12 weeks of starting therapy, (1) CBC, INR, hepatic function panel and GFR. Must document cirrhosis status, prior treatment history (if any), and planned duration of treatment. For all genotypes: trial with inadequate response, contraindication to, or intolerance to sofosbuvir/velpatasvir required prior to the approval of Vosevi or non-formulary products
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	Duration of approval per AASLD Guidelines
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

HETLIOZ

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of non-24-hour sleep-wake disorder, B.) Patient has documented blindness
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PS/UV/ADOL HS START
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate, F.) Moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy, G.) Moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants (e.g. corticosteroids, azathioprine), H.) Non-infectious uveitis (including intermediate, posterior, and panuveitis), or I.) Moderate to severe hidradenitis suppurativa. Screening for latent tuberculosis infection is required prior to initiation of treatment.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

IBRANCE

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with Faslodex (fulvestrant) and disease has progressed following endocrine therapy, B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with an aromatase inhibitor in postmenopausal women or men
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ICLUSIG

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated, or B.) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

IDHIFA

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of relapsed or refractory acute myeloid leukemia, B.) Patient has an isocitrate dehydrogenase 2 mutation as detected by a FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

IMBRUVICA

Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, B.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), C.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, D.) Waldenstrom's macroglobulinemia (WM), E.) Marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy, or F.) Graft vs host disease after failure of a least one first-line corticosteroid therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

INBRIJA

Products Affected

- INBRIJA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with nonselective monoamine oxidase inhibitors (MAOIs) (e.g. phenelzine and tranylcypromine) or recent use (within 2 weeks) with a nonselective MAOI
Required Medical Information	Must meet all of the following: A.) Diagnosis of Parkinson's disease, B.) Concurrent therapy with carbidopa/levodopa, C.) Patient has tried and failed or has contraindication to one generic formulary alternative
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Active or suspected malignancy, B.) Use for growth promotion in patients with closed epiphyses, C.) Intravenous administration
Required Medical Information	Diagnosis of one of the following A.) Growth failure in children with severe primary IGF-1 deficiency, or B.) Growth hormone (GH) gene deletion in children who have developed neutralizing antibodies to GH
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

INTRAROSA

Products Affected

- INTRAROSA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Vaginal bleeding or dysfunctional uterine bleeding of an undetermined origin, B.) Known or suspected estrogen-dependent neoplasia
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe dyspareunia due to menopause, or B.) Atrophic vaginitis due to menopause
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

IRESSA

Products Affected

- IRESSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of metastatic non-small cell lung cancer (NSCLC), B.) Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

JUXTAPID

Products Affected

- JUXTAPID

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests, B.) Pregnancy, or C.) Concomitant use with strong or moderate CYP3A4 inhibitors
Required Medical Information	Diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of cystic fibrosis, B.) Patient has a cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

KISQALI

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer and intended to be used in combination with an aromatase inhibitor in pre/perimenopausal or postmenopausal women, or B.) Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer used in combination with fulvestrant in postmenopausal women (requirement of fulvestrant applies to single agent Kisqali only, NOT Kisqali-Femara Co-pack)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy, B.) Coadministration with simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, C.) Concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses, D.) History of unexplained vaginal bleeding, E.) Endometrial hyperplasia with atypia or endometrial carcinoma
Required Medical Information	Diagnosis of endogenous Cushing syndrome in patients with type 2 diabetes mellitus or glucose intolerance and one of the following A.) Used to control hyperglycemia secondary to hypercortisolism and patient has failed surgery, or B.) Used to control hyperglycemia secondary to hypercortisolism and patient is not a candidate for surgery
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

KUVAN

Products Affected

- KUVAN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LENVIMA

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, B.) Advanced renal cell carcinoma following one prior anti-angiogenic therapy in combination with everolimus, C.) Unresectable liver carcinoma, or D.) Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, in a patient which has disease progression following prior systemic therapy and is not a candidate for curative surgery or radiation
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LEUKINE

Products Affected

- LEUKINE INJECTION SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with myelosuppressive chemotherapy or radiation or excessive (greater than or equal to 10%) leukemic myeloid blasts in bone marrow or peripheral blood
Required Medical Information	Must meet one of the following A.) Patient has undergone allogeneic or autologous bone marrow transplant (BMT) and engraftment is delayed or failed, B.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, C.) Medication will be used for myeloid reconstitution after an autologous or allogeneic BMT, D.) Patient has acute myeloid leukemia and administration will be after completion of induction chemotherapy, or E.) Diagnosis of hematopoietic subsyndrome of acute radiation syndrome (H-ARS)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LIDOCAINE PATCH

Products Affected

- *lidocaine external patch 5 %*
- ZTLIDO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Pain associated with diabetic neuropathy, B.) Pain associated with cancer-related neuropathy, C.) Post-herpetic neuralgia
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LORBRENA

Products Affected

- LORBRENA

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A4 inducers
Required Medical Information	Diagnosis of metastatic, anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer with disease progression on either alectinib or ceritinib as the first ALK inhibitor for metastatic disease, or disease progression on crizotinib and at least one other ALK inhibitor for metastatic disease
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LUPRON

Products Affected

- *leuprolide acetate injection*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy in patients with child-bearing potential, B.) Breastfeeding, C.) Undiagnosed abnormal vaginal bleeding
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic prostate cancer and patient has failed or is intolerant to Eligard (7.5 mg 1-month, 22.5 mg 3-month, 30 mg 4-month, & 45 mg 6-month depots only), B.) Endometriosis (3.75 mg 1-month & 11.25 mg 3-month depots only), C.) Anemia due to uterine leiomyomata (Fibroids) (3.75 mg 1-month & 11.25 mg 3-month depots only) and patient is preoperative, or D.) Central precocious puberty (idiopathic or neurogenic) in children
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

LYNPARZA

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) HER2- negative, deleterious or suspected deleterious germline BRCA mutated metastatic breast cancer AND patient has been previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, B.) Advanced ovarian cancer with known or suspected BRCA mutation as detected by an FDA-approved test AND patient has trial and failure, contraindication, or intolerance to 3 or more prior lines of chemotherapy, C.) Recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer AND used for maintenance treatment in patients who are in complete or partial response to platinum-based chemotherapy (e.g. cisplatin, carboplatin), D.) Deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to first-line platinum-based chemotherapy, or E.) Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma and disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MAYZENT

Products Affected

- MAYZENT

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) CYP2C9*3/*3 genotype, B.) In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, Class III-IV heart failure, or C.) Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker.
Required Medical Information	Diagnosis of relapsing form of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease and the following A.) Patients with relapsing forms of multiple sclerosis have history of/or contraindication to Avonex, Betaseron, Gilenya, or glatiramer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MEGESTROL

Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml*
- *megestrol acetate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives for diagnosis of cachexia secondary to chronic illness (dronabinol, oxandrolone)
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MEKINIST

Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and used in combination with dabrafenib and no locoregional treatment options, B.) Malignant melanoma with lymph node involvement and following complete resection with BRAF V600E or V600K mutations and used in combination with dabrafenib, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations and used in combination with dabrafenib or as monotherapy , or D.) Metastatic non-small cell lung cancer, with BRAF V600E mutation, in combination with dabrafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA approved test, B.) Used in combination with encorafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MIGLUSTAT

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of mild to moderate type 1 Gaucher disease, B.) Patient is not a candidate for enzyme replacement therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

MS INTERFERONS

Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT
- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hypoparathyroidism and used to control hypocalcemia
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of early stage HER2-overexpressed breast cancer, B.) Medication is being used after trastuzumab therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following A.) Diagnosis of multiple myeloma, B.) Patient has documentation of combination therapy with lenalidomide and dexamethasone, C.) Patient has tried 1 prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NORTHERA

Products Affected

- NORTHERA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of non-metastatic, castration-resistant prostate cancer
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NUCALA

Products Affected

- NUCALA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Severe asthma with eosinophilic phenotype, or B.) Eosinophilic granulomatosis with polyangiitis (EGPA)
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist, rheumatologist, or immunologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of prolonged QT interval, congenital long QT syndrome or Torsades de pointes, B.) Heart failure, C.) Complete AV block without an implanted pacemaker or high risk of complete AV block, D.) Concomitant use with quinidine, quinine, mefloquine, or drugs that prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide), E.) Concomitant use with MAOIs or within 14 days of MAOI therapy
Required Medical Information	Diagnosis of pseudobulbar affect
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hallucinations and delusions associated with Parkinson disease psychosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

OCTREOTIDE

Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acromegaly and patient has inadequate response to or is ineligible for surgery, radiation, or bromocriptine mesylate, B.) Metastatic carcinoid syndrome, or C.) Vasoactive intestinal peptide-secreting tumors (VIPomas) with associated diarrhea
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Must meet both of the following A.) Diagnosis of pulmonary arterial hypertension (WHO Group I), B.) Diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ORILISSA

Products Affected

- ORILISSA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy, B.) Known osteoporosis, C.) Severe hepatic impairment, D.) Concurrent use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors
Required Medical Information	Diagnosis of moderate to severe pain associated with endometriosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ORKAMBI

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

OSPHENA

Products Affected

- OSPHENA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Undiagnosed abnormal genital bleeding, B.) Known or suspected estrogen-dependent neoplasia, C.) Active or history of deep vein thrombosis, D.) Active or history of pulmonary embolism, E.) Active or history of arterial thromboembolic disease, F.) Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause, or B.) Moderate to severe vaginal dryness due to vulvar and vaginal atrophy associated with menopause
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

OXANDROLONE

Products Affected

- *oxandrolone oral*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Breast or prostate cancer in men, B.) Breast cancer in women with hypercalcemia, C.) Pregnancy, D.) Nephrosis or nephrotic phase of nephritis, E.) Hypercalcemia
Required Medical Information	Diagnosis one of the following and receiving treatment as an adjunct therapy to promote weight gain A.) Extensive surgery, B.) Chronic infections, C.) Severe trauma, or D.) Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons, E.) Chronic corticosteroid administration, F.) Bone pain associated with osteoporosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	3 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PCSK9 INHIBITOR

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>PRALUENT: Must meet criteria #1, #2 or #3. REPATHA: Must meet criteria #1, #2, #3 or #4. 1.) Diagnosis of primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH). 2.) Myocardial infarction prophylaxis, stroke prophylaxis, and to reduce risk of coronary revascularization in pts with established CVD. 3.) Diagnosis of clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following: a. acute coronary syndrome, b. history of myocardial infarction, c. stable/unstable angina, d. coronary or other arterial revascularization, e. stroke, f. transient ischemic stroke (TIA), g. peripheral arterial disease presumed to be atherosclerotic region. 4.) Primary hyperlipidemia homozygous familial hypercholesterolemia (HoFH) confirmed by genotyping OR diagnosis based on the following: a. History of untreated LDL-C greater than 500 mg/dL AND xanthoma before 10 years of age OR b. Documentation of HeFH in both parents. REQUIRED DOCUMENTATION FOR INITIAL THERAPY: A.) Baseline and current LDL-C, LDL-C greater than or equal to 70 mg/dL, AND used in combination with maximally tolerated high-intensity statin OR patient is statin intolerant and LDL-C greater than or equal to 70 mg/dL. FOR CONTINUING THERAPY: Will continue to be used in combination with maximally tolerated statin (unless statin intolerant).</p>
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist
Coverage Duration	Initial: 8 weeks, Renewal: Plan Year
Other Criteria	None

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PEGASYS

Products Affected

- PEGASYS PROCLICK
SUBCUTANEOUS SOLUTION 180
MCG/0.5ML
- PEGASYS SUBCUTANEOUS
SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Autoimmune hepatitis or other autoimmune condition known to be exacerbated by interferon, B.) Uncontrolled depression
Required Medical Information	Diagnosis of one of the following A.) Chronic hepatitis C and criteria applied consistent with current AASLD-IDSA guidance with compensated liver disease, or B.) Chronic hepatitis B infection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hepatologist, gastroenterologist, or infectious disease specialist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hormone receptor (HR) positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer and used in combination with fulvestrant for postmenopausal women, and men following progression on or after endocrine-based regimen.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

POMALYST

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Must meet all of the following A.) Disease has progressed on or within 60 days of completion of the last therapy, B.) If female of reproductive potential ALL of the below: Two negative pregnancy tests obtained prior to initiating therapy with Pomalyst, monthly negative pregnancy tests during therapy, C.) Patient has been counseled about the use of 2 forms of reliable contraception before, during, and 1 month after discontinuing therapy with Pomalyst, D.) Patient assessment to determine if prophylactic aspirin or antithrombic treatment (warfarin, clopidogrel) will need to be taken to reduce the risk of VTE (embolism, stroke), E.) Registered and certified to be compliant with Pomalyst REMS program
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PROMACTA

Products Affected

- PROMACTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic thrombocytopenic purpura (ITP), B.) Chronic hepatitis C infection associated thrombocytopenia, or C.) Severe aplastic anemia with insufficient response to immunosuppressive therapy or in combination with standard immunosuppressive therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

REVLIMID

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ROZLYTREK

Products Affected

- ROZLYTREK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following: A) ROS1-positive metastatic non-small cell lung cancer (NSCLC), OR B) Solid tumors that 1) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, AND 2) are metastatic or where surgical resection is likely to result in severe morbidity, AND 3) have either progressed following treatment or have no satisfactory alternative therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of 1. deleterious BRCA mutation (germline and/or somatic)-associated ovarian, fallopian tube, or primary peritoneal cancer and all of the following criteria (A-E): A.) BRCA mutation positive as detected by an approved FDA laboratory test, B.) Previous trial with inadequate response to two or more chemotherapy regimens, C.) Used as monotherapy, D.) Agreement of provider to perform a complete blood count (CBC) at baseline and monthly thereafter, E.) Women of reproductive potential must use an effective method of contraception during therapy and for 6 months after the last dose. Diagnosis of 2. Diagnosis of recurrent ovarian, fallopian tube, or primary peritoneal cancer and all of the following (A-D): A.) Complete or partial response to platinum-based chemotherapy B.) Used as monotherapy C.) Agreement of provider to perform a complete blood count (CBC) at baseline and monthly thereafter, D.) Women of reproductive potential must use an effective method of contraception during therapy and for 6 months after the last dose. Renewal will be based on lack of disease progression or unacceptable toxicity.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) treatment naive FLT3 mutation-positive acute myelogenous leukemia (AML) and must be used in combination with standard cytarabine and daunorubicin induction and consolidation therapy, or B.) systemic mastocytosis or mast cell leukemia.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SAMSCA

Products Affected

- SAMSCA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Use in patients unable to sense or respond to thirst, B.) Anuria, C.) Hypovolemic hyponatremia, D.) Urgent need to raise serum sodium acutely
Required Medical Information	Diagnosis of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L or less marks hyponatremia that is symptomatic and has resisted correction with fluid restriction), including in patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SILDENAFIL

Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Nitrate therapy
Required Medical Information	Must meet both of the following A.) Diagnosis of pulmonary arterial hypertension (WHO Group I), B.) Diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SKELETAL MUSCLE RELAXANTS

Products Affected

- *chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg*
- *metaxalone oral tablet 800 mg*
- *methocarbamol oral*
- *cyclobenzaprine hcl oral*
- *orphenadrine citrate er*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SOMATULINE

Products Affected

- SOMATULINE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acromegaly in patient with inadequate response to or is ineligible for surgery or radiotherapy, B.) Carcinoid syndrome, or C.) Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of acromegaly, B.) Patient has had inadequate response to or is ineligible for surgery or radiation therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SPRYCEL

Products Affected

- SPRYCEL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) that is newly diagnosed in the chronic phase, B.) Ph+ CML in chronic, accelerated, or lymphoid blast phase with resistance or intolerance to prior therapy, C.) Diagnosis of Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy, or D.) Newly diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severely active Crohn disease and patient has trial and failure or intolerance or contraindication to Humira, B.) Moderate to severe plaque psoriasis and patient has trial and failure or intolerance or contraindication to Humira and Enbrel, C.) Active psoriatic arthritis and patient has trial and failure or intolerance or contraindication to Humira and Enbrel, or D.) Moderate to severe active ulcerative colitis and patient has trial and failure or intolerance or contraindication to Humira
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist or gastroenterologist or dermatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic colorectal cancer in patients previously treated with ALL of the following per the indication: 1. (fluoropyrimidine-, oxaliplatin-, and irinotecan)-based chemotherapy 2. anti-VEGF bevacizumab 3. anti-EGFR panitumumab OR cetuximab (for KRAS mutation-negative patients only), B.) Liver carcinoma in patients previously treated with sorafenib, or C.) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib and sunitinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SUTENT

Products Affected

- SUTENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, B.) Pancreatic neuroendocrine tumors in a patient with unresectable locally advanced or metastatic disease, C.) Advanced renal cell carcinoma, or D.) Renal cell carcinoma and used as adjuvant therapy following nephrectomy in patients who are at high risk for recurrence
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SYLATRON

Products Affected

- SYLATRON SUBCUTANEOUS KIT
200 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Autoimmune hepatitis, B.) Hepatic decompensation (Child-Pugh score greater than 6 [Class B or C])
Required Medical Information	Must meet both of the following A.) Diagnosis of melanoma with microscopic or gross nodal involvement, B.) Medication will be used as adjuvant therapy within 84 days of definitive surgical resection, including complete lymphadenectomy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis and one of the following A.) Patient is homozygous for the F508del mutation, or B.) Patient has at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor verified by an FDA-cleared CF mutation test
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Confirmed diagnosis of gastroparesis, B.) Hypoglycemia unawareness
Required Medical Information	Diagnosis of one of the following A.) Type 1 diabetes mellitus and patient uses mealtime insulin therapy and has failed to achieve desired glucose control, or B.) Type 2 diabetes mellitus and patient uses mealtime insulin therapy and has failed to achieve desired glucose control
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TAFINLAR

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid carcinoma with BRAF V600E mutation, in combination with trametinib and no satisfactory locoregional treatment options, B.) Metastatic non-small cell lung cancer with BRAF V600E mutation, in combination with trametinib OR in patients previously treated as monotherapy, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutation AND 1) used as monotherapy OR 2) in combination with trametinib OR 3) used as adjuvant therapy following complete resection in patients with lymph node involvement AND used in combination with trametinib.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TAGRISO

Products Affected

- TAGRISO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic, non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation and used as first line therapy, or B.) Metastatic, non-small cell lung cancer with confirmed presence of T790M EGFR mutation AND whose disease has progressed on or after EGFR tyrosine kinase inhibitor based therapy (Diagnosis should be confirmed by an FDA-approved test)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TAKHZYRO

Products Affected

- TAKHZYRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary angioedema and used in prevention of attacks
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TASIGNA

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia, D.) Concomitant use with a drug known to prolong the QT interval or strong cytochrome P450 3A4 inhibitors
Required Medical Information	Diagnosis of one of the following A.) Newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic phase, B.) Chronic-phase and accelerated-phase Philadelphia chromosome-positive CML in patients resistant or intolerant to prior therapy that include imatinib, or C.) Chronic-phase Philadelphia chromosome-positive CML in patients with resistance or intolerance to prior tyrosine-kinase inhibitor therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TECFIDERA

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., relapsing-remitting MS or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TEGSEDI

Products Affected

- TEGSEDI

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Platelet count less than 100,000 per microliter, B.) Urinary protein to creatinine ratio (UPCR) of 1000 mg/g or higher
Required Medical Information	Diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TESTOSTERONES

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HOUR (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%),
- testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1%)
- testosterone transdermal solution

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Carcinoma of the breast (males only) or prostate, B.) Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, B.) Inoperable metastatic breast cancer in women who are postmenopausal, or C.) Primary hypogonadism. Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TETRABENAZINE

Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Actively suicidal, B.) Untreated or inadequately treated depression, C.) Impaired hepatic function, D.) Concomitant use of monoamine oxidase inhibitors, E.) Concomitant use of reserpine or within 20 days of discontinuing reserpine
Required Medical Information	Diagnosis of chorea associated with Huntington's disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

THALOMID

Products Affected

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma that is newly diagnosed, or B.) Erythema nodosum leprosum (ENL)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or infectious disease specialist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acute myeloid leukemia in relapsed or refractory patients, with susceptible isocitrate dehydrogenase-1 mutation, or B.) Acute myeloid leukemia in newly-diagnosed patients, with susceptible isocitrate dehydrogenase-1 mutation AND one of the following 1.) patient is 75 years or older , or 2.) patient has comorbidities that preclude intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TRACLEER

Products Affected

- TRACLEER ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Receiving concomitant cyclosporine A or glyburide therapy, B.) Aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin at least 2 times the upper limit of normal, C.) Pregnancy
Required Medical Information	Must meet both of the following A.) Diagnosis of pulmonary arterial hypertension (WHO Group I), B.) Diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TRIKAFTA

Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis and patient has at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene verified by an FDA-cleared CF mutation test
Age Restrictions	12 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

UPTRAVI

Products Affected

- UPTRAVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization and patient has tried and had an insufficient response to at least one other PAH agent (e.g., sildenafil) therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A inhibitor during the initial and titration phase in patients with CLL or SLL
Required Medical Information	Diagnosis of one of the following A.) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or B.) Newly-diagnosed acute myeloid leukemia (AML) and used in combination with azacitidine, decitabine or low-dose cytarabine in patients 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic, HER2-negative, hormone receptor-positive breast cancer AND one of the following: A.) For postmenopausal women must be used in combination with fulvestrant for the treatment of disease progression following endocrine therapy and patient has had trial and failure or contraindication to Ibrance or Kisqali, B.) For premenopausal or perimenopausal women must be used in combination with fulvestrant for the treatment of disease progression following endocrine therapy and patient has had trial with inadequate response or contraindication to Ibrance, C.) Used as monotherapy for treatment of disease progression following endocrine therapy and patient has already received at least one prior chemotherapy regimen of Ibrance or Kisqali, D.) For postmenopausal women used as initial endocrine-based treatment in combination with an aromatase inhibitor and patient has had trial with inadequate response or contraindication to Kisqali or Ibrance, E.) For premenopausal or perimenopausal women used as initial endocrine-based treatment in combination with an aromatase inhibitor and patient has had trial with inadequate response or contraindication to Kisqali
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

VITRAKVI

Products Affected

- VITRAKVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet both of the following A.) Diagnosis of metastatic or surgically unresectable neurotrophic receptor tyrosine kinase (NTRK) gene fusion-positive solid tumors, B.) Used in patients with unsatisfactory alternative treatments or who have progressed following treatment
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

VIZIMPRO

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

VYNDAMAX

Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of wild type or hereditary transthyretin related familial amyloid cardiomyopathy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XALKORI

Products Affected

- XALKORI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS1-positive as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR ORAL TABLET
EXTENDED RELEASE 24 HOUR 11
MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Psoriatic arthritis (PsA) or Rheumatoid arthritis (RA) (Initial): Diagnosis of psoriatic arthritis or moderately to severely active RA and an inadequate response or intolerance to methotrexate. One of the following: Failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab), OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria), OR for continuation of prior tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine). Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Patient is corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC), OR history of failure, contraindication, or intolerance to one of the following: oral aminosalicylate, oral corticosteroid, azathioprine, 6-mercaptopurine AND one of the following: failure, contraindication, or intolerance to Humira (adalimumab).
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist or gastroenterologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.

Formulary ID 20202, Ver 9
Last Updated 2/25/2020
Effective 3/1/2020

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PA Criteria	Criteria Details
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia (calcium less than 8.0 mg/dL)
Required Medical Information	Diagnosis of one of the following A.) Bone metastases from a solid tumor, B.) Giant cell tumor of the bone that is unresectable or where surgical resection is likely to result in severe morbidity, C.) Hypercalcemia of malignancy refractory to bisphosphonate therapy, or D.) Multiple myeloma used for the prevention of skeletal related events
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic urticaria in patients who remain symptomatic despite H1 antihistamine therapy, or B.) Moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms are inadequately controlled with inhaled corticosteroids
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or dermatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory acute myeloid leukemia, with presence of FLT3 mutation as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XPOVIO

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory multiple myeloma being used in combination with dexamethasone in patient who has received at least 4 prior therapies and is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XTANDI

Products Affected

- XTANDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant prostate cancer (CRPC), or B) Metastatic castration-sensitive prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XURIDEN

Products Affected

- XURIDEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary orotic aciduria
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

XYREM

Products Affected

- XYREM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency
Required Medical Information	Diagnosis of cataplexy and excessive daytime sleepiness in patients with narcolepsy
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

YONSA

Products Affected

- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy, B.) Patients with severe baseline hepatic impairment (Child-Pugh Class C)
Required Medical Information	Diagnosis of metastatic castration-resistant prostate cancer and meets both of the following A.) Used in combination with methylprednisolone, B.) Documented history of trial with, inadequate treatment response, adverse event, or contraindication to Zytiga (abiraterone)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ZEJULA

Products Affected

- ZEJULA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer and used for maintenance therapy in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin), or B.) advanced ovarian, fallopian tube, or primary peritoneal cancer and patient has been treated with 3 or more prior chemotherapy regimens, and cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability, and disease has progressed more than 6 months after response to the last platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or gynecologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ZYKADIA

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

ZYTIGA

Products Affected

- *abiraterone acetate*
- ZYTIGA ORAL TABLET 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant metastatic prostate cancer and used in combination with prednisone, or B.) High risk, castration-sensitive metastatic prostate cancer and used in combination with prednisone
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

PART B VERSUS PART D

Products Affected

- ABELCET
- *acetylcysteine inhalation*
- *acyclovir sodium intravenous solution*
- *albuterol sulfate inhalation*
- AMBISOME
- AMINOSYN II INTRAVENOUS SOLUTION 10 %
- AMINOSYN-PF
- *amphotericin b intravenous*
- *aprepitant*
- AZASAN
- *azathioprine oral*
- *budesonide inhalation*
- *calcitonin (salmon)*
- *caspofungin acetate*
- *chlorpromazine hcl oral tablet 10 mg, 25 mg*
- *cinacalcet hcl*
- CLINIMIX E/DEXTROSE (2.75/5)
- CLINIMIX E/DEXTROSE (4.25/10)
- CLINIMIX E/DEXTROSE (4.25/5)
- CLINIMIX E/DEXTROSE (5/15)
- CLINIMIX E/DEXTROSE (5/20)
- CLINIMIX/DEXTROSE (4.25/10)
- CLINIMIX/DEXTROSE (4.25/5)
- CLINIMIX/DEXTROSE (5/15)
- CLINIMIX/DEXTROSE (5/20)
- CLINISOL SF
- *colistimethate sodium (cba)*
- *cromolyn sodium inhalation*
- *cyclophosphamide oral capsule*
- *cyclosporine modified*
- *cyclosporine oral capsule*
- DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML
- *dextrose intravenous solution 10 %, 5 %*
- *diphtheria-tetanus toxoids dt*
- *duramorph*
- ENGERIX-B INJECTION
- ENVARUS XR
- FIRMAGON
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- FREAMINE HBC
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C
- GENGRAF ORAL CAPSULE 100 MG, 25 MG
- GENGRAF ORAL SOLUTION
- *granisetron hcl oral*
- HEPATAMINE
- IMOVAX RABIES
- INTRALIPID
- INTRON A
- *ipratropium bromide inhalation*
- *ipratropium-albuterol*
- *levalbuterol hcl inhalation*
- *levocarnitine oral solution*
- *levocarnitine oral tablet*
- *methotrexate oral*
- *methotrexate sodium (pf) injection solution 50 mg/2ml*
- *methotrexate sodium injection solution 50 mg/2ml*
- *mycophenolate mofetil*
- *mycophenolate sodium*
- NEBUPENT
- NEPHRAMINE
- *nutrilipid*
- *ondansetron*
- *ondansetron hcl oral*
- *pentamidine isethionate inhalation*
- PLENAMINE
- PREMASOL
- PROCALAMINE
- PROGRAF ORAL PACKET
- PROSOL
- PULMOZYME
- RABAVERT

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

- RECOMBIVAX HB
- SANDIMMUNE ORAL SOLUTION
- *sirolimus oral*
- *tacrolimus oral*
- TDVAX
- TENIVAC
- *tigecycline*
- *tobramycin inhalation*
- TPN ELECTROLYTES INTRAVENOUS SOLUTION
- TRAVASOL
- TRELSTAR MIXJECT
- TREXALL
- TROPHAMINE INTRAVENOUS SOLUTION 10 %
- XATMEP
- ZORTRESS

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

Index

A

ABELCET.....	148
abiraterone acetate	147
acetylcysteine inhalation.....	148
ACTIMMUNE.....	1
acyclovir sodium intravenous solution ...	148
ADEMPAS	2
albuterol sulfate inhalation.....	148
ALECENSA.....	3
ALUNBRIG.....	5
AMBISOME.....	148
ambrisentan	6
AMINOSYN II INTRAVENOUS SOLUTION 10 %	148
AMINOSYN-PF	148
amphotericin b intravenous.....	148
ANDRODERM TRANSDERMAL PATCH 24 HOUR	121
aprepitant.....	148
ARCALYST	8
ARIKAYCE.....	9
armodafinil.....	22
ASCOMP-CODEINE	7
AUBAGIO	10
AURYXIA	11
AUSTEDO.....	12
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT.....	77
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT.....	77
AZASAN	148
azathioprine oral.....	148

B

BALVERSA	13
BETASERON SUBCUTANEOUS KIT ..	77
bosentan	14
BOSULIF.....	15
BRAFTOVI ORAL CAPSULE 75 MG ...	16
BRUKINSA	17
budesonide inhalation	148
butalbital-apap-caff-cod oral capsule 50- 325-40-30 mg.....	7

butalbital-apap-caffeine oral tablet 50-325- 40 mg	7
butalbital-asa-caff-codeine.....	7
butalbital-aspirin-caffeine oral capsule.....	7
C	
CABLIVI	18
CABOMETYX	19
calcitonin (salmon).....	148
CALQUENCE	20
casprofungin acetate.....	148
CAYSTON.....	21
chlorpromazine hcl oral tablet 10 mg, 25 mg	148
chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg	104
cinacalcet hcl.....	148
CLINIMIX E/DEXTROSE (2.75/5).....	148
CLINIMIX E/DEXTROSE (4.25/10).....	148
CLINIMIX E/DEXTROSE (4.25/5).....	148
CLINIMIX E/DEXTROSE (5/15).....	148
CLINIMIX E/DEXTROSE (5/20).....	148
CLINIMIX/DEXTROSE (4.25/10)	148
CLINIMIX/DEXTROSE (4.25/5)	148
CLINIMIX/DEXTROSE (5/15)	148
CLINIMIX/DEXTROSE (5/20)	148
CLINISOL SF.....	148
colistimethate sodium (cba)	148
COPIKTRA.....	23
COSENTYX (300 MG DOSE).....	24
COSENTYX SENSOREADY (300 MG). ..	24
COTELIC	25
cromolyn sodium inhalation	148
cyclobenzaprine hcl oral	104
cyclophosphamide oral capsule	148
cyclosporine modified.....	148
cyclosporine oral capsule.....	148
CYSTARAN.....	26
D	
dalfampridine er	27
DAURISMO	28
deferasirox oral tablet 360 mg, 90 mg	29
deferasirox oral tablet soluble.....	29
DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML.....	148

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

dextrose intravenous solution 10 %, 5 %	148	GILENYA ORAL CAPSULE 0.5 MG.....	43
diclofenac sodium transdermal gel 3 %	30	GILOTRIF	44
diphtheria-tetanus toxoids dt.....	148	glatiramer acetate	45
dronabinol	31	GOCOVRI	46
duramorph.....	148	granisetron hcl oral	148
E		H	
ENBREL MINI.....	32	HEPATAMINE.....	148
ENBREL SUBCUTANEOUS SOLUTION		HETLIOZ.....	50
PREFILLED SYRINGE	32	HUMIRA PEDIATRIC CROHNS START	
ENBREL SUBCUTANEOUS SOLUTION		SUBCUTANEOUS PREFILLED	
RECONSTITUTED.....	32	SYRINGE KIT.....	51
ENBREL SURECLICK SUBCUTANEOUS		HUMIRA PEN SUBCUTANEOUS PEN-	
SOLUTION AUTO-INJECTOR	32	INJECTOR KIT	51
ENDARI	33	HUMIRA PEN-CD/UC/HS STARTER ...	51
ENGERIX-B INJECTION.....	148	HUMIRA PEN-PS/UV/ADOL HS START	
ENVARUSUS XR.....	148	51
EPIDIOLEX.....	34	HUMIRA SUBCUTANEOUS PREFILLED	
ERLEADA	35	SYRINGE KIT.....	51
ESBRIET ORAL CAPSULE.....	36	I	
ESBRIET ORAL TABLET 801 MG.....	36	IBRANCE	52
F		ICLUSIG.....	53
FARYDAK	38	IDHIFA	54
FASENRA	39	IMBRUVICA.....	55
FASENRA PEN.....	39	IMOVAX RABIES.....	148
fentanyl citrate buccal lozenge on a handle		INBRIJA	56
.....	40	INCRELEX.....	57
FIRDAPSE.....	41	INREBIC.....	58
FIRMAGON	148	INTRALIPID	148
FLEBOGAMMA DIF INTRAVENOUS		INTRAROSA.....	59
SOLUTION 5 GM/50ML	148	INTRON A.....	148
FREAMINE HBC.....	148	ipratropium bromide inhalation	148
G		ipratropium-albuterol	148
GALAFOLD	42	IRESSA.....	60
GAMMAGARD INJECTION SOLUTION		J	
2.5 GM/25ML.....	148	JUXTAPID	61
GAMMAGARD S/D LESS IGA.....	148	K	
GAMMAKED INJECTION SOLUTION 1		KALYDECO.....	62
GM/10ML.....	148	KISQALI (200 MG DOSE).....	63
GAMMAPLEX INTRAVENOUS		KISQALI (400 MG DOSE).....	63
SOLUTION 10 GM/100ML, 10		KISQALI (600 MG DOSE).....	63
GM/200ML, 20 GM/200ML, 5		KISQALI FEMARA (400 MG DOSE)	63
GM/50ML.....	148	KISQALI FEMARA (600 MG DOSE)	63
GAMUNEX-C	148	KISQALI FEMARA(200 MG DOSE)	63
GENGRAF ORAL CAPSULE 100 MG, 25		KORLYM	64
MG	148	KUVAN	65
GENGRAF ORAL SOLUTION.....	148		

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

L		NORTHERA	81
LENVIMA (10 MG DAILY DOSE)	66	NUBEQA.....	82
LENVIMA (12 MG DAILY DOSE)	66	NUCALA.....	83
LENVIMA (14 MG DAILY DOSE)	66	NUDEXTA.....	84
LENVIMA (18 MG DAILY DOSE)	66	NUPLAZID ORAL CAPSULE.....	85
LENVIMA (20 MG DAILY DOSE)	66	NUPLAZID ORAL TABLET 10 MG.....	85
LENVIMA (24 MG DAILY DOSE)	66	nutrilipid.....	148
LENVIMA (4 MG DAILY DOSE)	66	O	
LENVIMA (8 MG DAILY DOSE)	66	octreotide acetate injection solution 100	
LEUKINE INJECTION SOLUTION		mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50	
RECONSTITUTED.....	67	mcg/ml, 500 mcg/ml	86
leuprolide acetate injection	70	OMNITROPE	47, 48
levabuterol hcl inhalation.....	148	ondansetron	148
levocarnitine oral solution.....	148	ondansetron hcl oral.....	148
levocarnitine oral tablet.....	148	OPSUMIT	87
lidocaine external patch 5 %	68	ORILISSA.....	88
LORBRENA.....	69	ORKAMBI.....	89
LUPRON DEPOT (1-MONTH)	70	orphenadrine citrate er	104
LUPRON DEPOT (3-MONTH)	70	OSPHERA.....	90
LUPRON DEPOT (4-MONTH)	70	oxandrolone oral	91
LUPRON DEPOT (6-MONTH)	70	P	
LYNPARZA ORAL TABLET	71	PEGASYS PROCLICK SUBCUTANEOUS	
M		SOLUTION 180 MCG/0.5ML	94
MAYZENT.....	72	PEGASYS SUBCUTANEOUS SOLUTION	
megestrol acetate oral suspension 40 mg/ml,		94
625 mg/5ml	73	pentamidine isethionate inhalation	148
megestrol acetate oral tablet.....	73	PIQRAY (200 MG DAILY DOSE).....	95
MEKINIST	74	PIQRAY (250 MG DAILY DOSE).....	95
MEKTOVI.....	75	PIQRAY (300 MG DAILY DOSE).....	95
metaxalone oral tablet 800 mg.....	104	PLENAMINE	148
methocarbamol oral	104	POMALYST	96
methotrexate oral	148	PRALUENT SUBCUTANEOUS	
methotrexate sodium (pf) injection solution		SOLUTION AUTO-INJECTOR	92, 93
50 mg/2ml	148	PRALUENT SUBCUTANEOUS	
methotrexate sodium injection solution 50		SOLUTION PEN-INJECTOR.....	92, 93
mg/2ml	148	PREMASOL	148
miglustat.....	76	PROCALAMINE.....	148
modafinil	22	PROGRAF ORAL PACKET.....	148
mycophenolate mofetil.....	148	PROLASTIN-C INTRAVENOUS	
mycophenolate sodium	148	SOLUTION RECONSTITUTED.....	4
N		PROMACTA	97
NATPARA.....	78	PROSOL	148
NEBUPENT.....	148	PULMOZYME	148
NEPHRAMINE	148	R	
NERLYNX	79	RABAVERT.....	148
NINLARO.....	80	RECOMBIVAX HB	149

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

REPATHA	92, 93	mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%),
REPATHA PUSHTRONEX SYSTEM... 92,	93	50 mg/5gm (1%)
REPATHA SURECLICK.....	92, 93	testosterone transdermal solution.....
RETACRIT.....	37	tetrabenazine
REVLIMID.....	98	THALOMID
ROZLYTREK.....	99	TIBSOVO
RUBRACA	100	tigecycline
RYDAPT.....	101	tobramycin inhalation
S		TPN ELECTROLYTES INTRAVENOUS
SAMSCA	102	SOLUTION.....
SANDIMMUNE ORAL SOLUTION	149	TRACLEER ORAL TABLET SOLUBLE
sildenafil citrate oral tablet 20 mg	103
sirolimus oral	149	TRAVASOL
sofosbuvir-velpatasvir.....	49	TRELSTAR MIXJECT
SOMATULINE DEPOT.....	105	TREXALL
SOMAVERT.....	106	TRIKAFTA.....
SPRYCEL.....	107	TROPHAMINE INTRAVENOUS
STELARA SUBCUTANEOUS		SOLUTION 10 %
SOLUTION 45 MG/0.5ML.....	108	TURALIO
STELARA SUBCUTANEOUS		U
SOLUTION PREFILLED SYRINGE	108	UPTRAVI.....
STIVARGA	109	V
SUTENT	110	VENCLEXTA.....
SYLATRON SUBCUTANEOUS KIT 200		VENCLEXTA STARTING PACK
MCG, 300 MCG, 600 MCG	111	VERZENIO.....
SYMDEKO.....	112	VITRAKVI
SYMLINPEN 120 SUBCUTANEOUS		VIZIMPRO
SOLUTION PEN-INJECTOR.....	113	VOSEVI.....
SYMLINPEN 60 SUBCUTANEOUS		VYNDAMAX.....
SOLUTION PEN-INJECTOR.....	113	X
T		XALKORI.....
tacrolimus oral	149	XATMEP
TAFINLAR.....	114	XELJANZ.....
TAGRISSE.....	115	XELJANZ XR ORAL TABLET
TAKHZYRO.....	116	EXTENDED RELEASE 24 HOUR 11
TALZENNA	117	MG
TASIGNA	118	XGEVA.....
TDVAX.....	149	XOLAIR
TECFIDERA.....	119	XOSPATA
TEGSEDI.....	120	XPOVIO (100 MG ONCE WEEKLY)...
TENIVAC	149	XPOVIO (60 MG ONCE WEEKLY)....
testosterone transdermal gel 10 mg/act (2%),		XPOVIO (80 MG ONCE WEEKLY).....
12.5 mg/act (1%), 20.25 mg/1.25gm		XPOVIO (80 MG TWICE WEEKLY)...
(1.62%), 20.25 mg/act (1.62%), 25		XTANDI
		XURIDEN.....
		XYREM

CARE N' CARE HEALTH PLAN

2020 Prior Authorization Criteria

Y		ZORTRESS	149
YONSA	144	ZTLIDO	68
Z		ZYKADIA ORAL TABLET	146
ZEJULA	145	ZYTIGA ORAL TABLET 500 MG	147